<DOC>
	<DOCNO>NCT02398058</DOCNO>
	<brief_summary>This Phase 1b , multi-site , open-label , non-randomized clinical trial evaluate safety , tolerability , pharmacokinetics escalate dos olaparib trabectedin patient unresectable advanced/metastatic sarcoma . Patients continue treat combination regimen absence disease progression , intolerable toxicity patient 's decision .</brief_summary>
	<brief_title>Trabectedin Plus Olaparib Metastatic Advanced Sarcomas ( TOMAS )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>write informed consent histologically document surgically resectable metastatic sarcoma progress first line treatment relapse disease Measurable disease define RECIST v1.1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0/1 . ECOG PS 2 eligible depends solely orthopedic problem Estimated life expectancy ≥ 4 month Age ≥18 year Adequate organ function : Hemoglobin &gt; 10.0 g/dl ; Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 ; Platelet count &gt; = 100,000/μl ; Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; ALT AST &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver involvement cancer ) ; Alkaline phosphatase &lt; 2.5 x ULN ; PTINR/PTT &lt; 1.5 x ULN ; Serum creatinine &lt; 1.5 x ULN creatinine clearance ≥ 50 ml/min ; Albumin &gt; 25 g/l ; Creatine phosphokinase ( CPK ) &lt; 2.5 x ULN Involvement plan and/or conduct study Previous enrolment present study Participation another clinical study investigational product last month Persistent toxicity ( ≥CTCAE grade 2 ) exception alopecia , cause previous anticancer therapy Dementia significantly alter mental status Patients severe and/or uncontrolled medical condition HIV infection Active clinically serious infection ( &gt; grade 2 NCICTCAE version 4.03 ) . Active viral hepatitis ( HBV HCV infection ) Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , require corticosteroid treatment , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) . Patients seizure disorder require medication ( steroids antiepileptic ) Pregnant breastfeed patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial 5 month last dose study drug Patients evidence history bleed diathesis Patients undergoing renal dialysis Patients unable swallow oral medication Uncontrolled diabetes ( fast glucose &gt; 2 x ULN ) Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent ( except corticosteroid daily dosage equivalent prednisone ≤ 20 mg adrenal insufficiency ) . Topical inhale corticosteroid permit Patients history another malignancy within 5 year prior study entry , except curatively treat nonmelanotic skin cancer insitu cervical cancer solid tumor curatively treat evidence disease ≥5 year . Anticancer chemotherapy immunotherapy study within 4 week treatment start Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow ) Major surgery within 4 week start study Prior exposure study drug analogues Patients know hypersensitivity trabectedin , olaparib excipients Patients receive stable dose bisphosphonates bone metastasis study long start least 4 week prior treatment study drug Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result A history noncompliance medical regimen inability unwillingness return schedule visit Corrected QT interval 12lead ECG ( QTc ) &gt; 470 msec ( Bazett Formula ) use strong CYP3A4 inhibitors/inducers Patients myelodysplastic syndrome/acute myeloid leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>trabectedin</keyword>
	<keyword>olaparib</keyword>
	<keyword>sarcoma</keyword>
	<keyword>bone tumor</keyword>
</DOC>